Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer

Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer

The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2010-12, Vol.82 (12), p.57
Hauptverfasser: Schauner, Stephanie, Lyon, Corey
Format: Artikel
Sprache:eng
Schlagworte:
Cervical cancer
Disease prevention
Effectiveness
Human papillomavirus
Safety
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 12
container_start_page 57
container_title American family physician
container_volume 82
creator Schauner, Stephanie
Lyon, Corey
description The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gardasil), Cervarix doesn't provide protection against HPV types 6 and 11, which are responsible for 90% of genital warts in males and females. Here, Schauner and Lyon look at the safety, tolerability, and effectiveness of Cervarix.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_847307489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248755741</sourcerecordid><originalsourceid>FETCH-proquest_journals_8473074893</originalsourceid><addsrcrecordid>eNqNi70KwjAURjMoWH_e4eKkQyHaStPVonSsIsWtXMMtptREk7b4-EbwAZw-Dud8IxZwzrehiMR1wqbONR6T3SYN2GmvBmxJd5AXJZxJmsdNafRcopRKE6wysgNa9V5DbSx0d4LC0uAvymgwNXy9kthChlqSnbNxja2jxW9nbHk8XLI8fFrz6sl1VWN6q72qRJxEPIlFGv0VfQBD9z2C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>847307489</pqid></control><display><type>article</type><title>Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Schauner, Stephanie ; Lyon, Corey</creator><creatorcontrib>Schauner, Stephanie ; Lyon, Corey</creatorcontrib><description>The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gardasil), Cervarix doesn't provide protection against HPV types 6 and 11, which are responsible for 90% of genital warts in males and females. Here, Schauner and Lyon look at the safety, tolerability, and effectiveness of Cervarix.</description><identifier>ISSN: 0002-838X</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>Leawood: American Academy of Family Physicians</publisher><subject>Cervical cancer ; Disease prevention ; Effectiveness ; Human papillomavirus ; Safety ; Vaccines</subject><ispartof>American family physician, 2010-12, Vol.82 (12), p.57</ispartof><rights>Copyright American Academy of Family Physicians Dec 15, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Schauner, Stephanie</creatorcontrib><creatorcontrib>Lyon, Corey</creatorcontrib><title>Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer</title><title>American family physician</title><description>The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gardasil), Cervarix doesn't provide protection against HPV types 6 and 11, which are responsible for 90% of genital warts in males and females. Here, Schauner and Lyon look at the safety, tolerability, and effectiveness of Cervarix.</description><subject>Cervical cancer</subject><subject>Disease prevention</subject><subject>Effectiveness</subject><subject>Human papillomavirus</subject><subject>Safety</subject><subject>Vaccines</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNi70KwjAURjMoWH_e4eKkQyHaStPVonSsIsWtXMMtptREk7b4-EbwAZw-Dud8IxZwzrehiMR1wqbONR6T3SYN2GmvBmxJd5AXJZxJmsdNafRcopRKE6wysgNa9V5DbSx0d4LC0uAvymgwNXy9kthChlqSnbNxja2jxW9nbHk8XLI8fFrz6sl1VWN6q72qRJxEPIlFGv0VfQBD9z2C</recordid><startdate>20101215</startdate><enddate>20101215</enddate><creator>Schauner, Stephanie</creator><creator>Lyon, Corey</creator><general>American Academy of Family Physicians</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20101215</creationdate><title>Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer</title><author>Schauner, Stephanie ; Lyon, Corey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_8473074893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Cervical cancer</topic><topic>Disease prevention</topic><topic>Effectiveness</topic><topic>Human papillomavirus</topic><topic>Safety</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schauner, Stephanie</creatorcontrib><creatorcontrib>Lyon, Corey</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schauner, Stephanie</au><au>Lyon, Corey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer</atitle><jtitle>American family physician</jtitle><date>2010-12-15</date><risdate>2010</risdate><volume>82</volume><issue>12</issue><spage>57</spage><pages>57-</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the US for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia caused by HPV types 16 and 18. Unlike the quadrivalent HPV vaccine (Gardasil), Cervarix doesn't provide protection against HPV types 6 and 11, which are responsible for 90% of genital warts in males and females. Here, Schauner and Lyon look at the safety, tolerability, and effectiveness of Cervarix.</abstract><cop>Leawood</cop><pub>American Academy of Family Physicians</pub></addata></record>
fulltext fulltext
identifier ISSN: 0002-838X
ispartof American family physician, 2010-12, Vol.82 (12), p.57
issn 0002-838X
language eng
recordid cdi_proquest_journals_847307489
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Cervical cancer
Disease prevention
Effectiveness
Human papillomavirus
Safety
Vaccines
title Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A03%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bivalent%20HPV%20Recombinant%20Vaccine%20(Cervarix)%20for%20the%20Prevention%20of%20Cervical%20Cancer&rft.jtitle=American%20family%20physician&rft.au=Schauner,%20Stephanie&rft.date=2010-12-15&rft.volume=82&rft.issue=12&rft.spage=57&rft.pages=57-&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest%3E2248755741%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=847307489&rft_id=info:pmid/&rfr_iscdi=true